Palatin Technologies Stock Gains After Closing Public Offering and Resuming NYSE Trading
Palatin Technologies, Inc. (NYSE American: PTN) saw its stock price rise after announcing the closing of an upsized public offering of $18.2 million on Nov. 12, 2025. The offering included the full exercise of the underwriters' option to purchase additional shares. The biopharmaceutical company's stock resumed trading on the NYSE American exchange the same day under its ticker symbol PTN.
The successful offering has brought Palatin back into compliance with the NYSE American's continued listing standards. The company intends to use the net proceeds to support the development of its obesity program, as well as for working capital and general corporate purposes. The offering was led by institutional investors focused on healthcare and saw participation from company executives and board members.
In its first-quarter fiscal year 2026 financial results, Palatin reported revenue of $8.85 million and net income of $4.7 million. The company also highlighted recent pipeline advancements, including progress in its melanocortin-based therapies for obesity. An Investigational New Drug (IND) submission for its oral small molecule, PL7737, is planned for the first half of 2026.
Palatin's focus is on developing medicines that modulate the activity of the melanocortin receptor system to treat diseases with unmet medical needs. The company's mission and vision are centered on this novel class of drugs. Key programs in its clinical pipeline include treatments for dry eye disease, ulcerative colitis, and obesity. Further information on the company's history and ownership is available for investors.
Palatin Technologies, Inc. (PTN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.